000168555 001__ 168555
000168555 005__ 20240229133611.0
000168555 0247_ $$2doi$$a10.3389/fonc.2021.616831
000168555 0247_ $$2pmid$$apmid:33912447
000168555 0247_ $$2pmc$$apmc:PMC8071947
000168555 037__ $$aDKFZ-2021-00972
000168555 041__ $$aEnglish
000168555 082__ $$a610
000168555 1001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b0$$eFirst author$$udkfz
000168555 245__ $$aThe Particle Radiobiology of Multipotent Mesenchymal Stromal Cells: A Key to Mitigating Radiation-Induced Tissue Toxicities in Cancer Treatment and Beyond?
000168555 260__ $$aLausanne$$bFrontiers Media$$c2021
000168555 3367_ $$2DRIVER$$aarticle
000168555 3367_ $$2DataCite$$aOutput Types/Journal article
000168555 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685523305_22950$$xReview Article
000168555 3367_ $$2BibTeX$$aARTICLE
000168555 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168555 3367_ $$00$$2EndNote$$aJournal Article
000168555 500__ $$a#EA:E055#LA:E055#
000168555 520__ $$aMesenchymal stromal cells (MSCs) comprise a heterogeneous population of multipotent stromal cells that have gained attention for the treatment of irradiation-induced normal tissue toxicities due to their regenerative abilities. As the vast majority of studies focused on the effects of MSCs for photon irradiation-induced toxicities, little is known about the regenerative abilities of MSCs for particle irradiation-induced tissue damage or the effects of particle irradiation on the stem cell characteristics of MSCs themselves. MSC-based therapies may help treat particle irradiation-related tissue lesions in the context of cancer radiotherapy. As the number of clinical proton therapy centers is increasing, there is a need to decidedly investigate MSC-based treatments for particle irradiation-induced sequelae. Furthermore, therapies with MSCs or MSC-derived exosomes may also become a useful tool for manned space exploration or after radiation accidents and nuclear terrorism. However, such treatments require an in-depth knowledge about the effects of particle radiation on MSCs and the effects of MSCs on particle radiation-injured tissues. Here, the existing body of evidence regarding the particle radiobiology of MSCs as well as regarding MSC-based treatments for some typical particle irradiation-induced toxicities is presented and critically discussed.
000168555 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000168555 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168555 650_7 $$2Other$$amesenchymal stem cells
000168555 650_7 $$2Other$$amesenchymal stromal cells
000168555 650_7 $$2Other$$anormal tissue toxicities
000168555 650_7 $$2Other$$aparticle irradiation
000168555 650_7 $$2Other$$aradiation accidents
000168555 650_7 $$2Other$$aradiotherapy
000168555 650_7 $$2Other$$aspace irradiation
000168555 650_7 $$2Other$$astem cell therapy
000168555 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b1
000168555 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b2$$eLast author$$udkfz
000168555 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2021.616831$$gVol. 11, p. 616831$$p616831$$tFrontiers in oncology$$v11$$x2234-943X$$y2021
000168555 909CO $$ooai:inrepo02.dkfz.de:168555$$pVDB
000168555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000168555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168555 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000168555 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000168555 9141_ $$y2021
000168555 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2019$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-27
000168555 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000168555 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000168555 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000168555 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x1
000168555 980__ $$ajournal
000168555 980__ $$aVDB
000168555 980__ $$aI:(DE-He78)E055-20160331
000168555 980__ $$aI:(DE-He78)FR01-20160331
000168555 980__ $$aUNRESTRICTED